Pfizer (NYSE:PFE) Trading Down 1% - Should You Sell?

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) dropped 1% on Friday . The company traded as low as $21.28 and last traded at $21.37. Approximately 14,183,509 shares changed hands during trading, a decline of 65% from the average daily volume of 40,058,298 shares. The stock had previously closed at $21.59.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, UBS Group cut their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Trading Up 0.9 %

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $125.34 billion, a P/E ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business's 50-day moving average is $25.25 and its 200 day moving average is $26.38.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $28,000. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.